Disseminated toxoplasmosis and toxoplasma encephalitis
Conditions
Interventions
Sponsors
Maruyama Haruhiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Confirmed toxoplasmosis patients (DNA positive) Suspected toxoplasmosis patients #1 typical brain imaging #2 serum anti-Toxoplasma IgG positive #3 other diseases are excluded
Exclusion criteria
Exclusion criteria: #1 HIV positive patients #2 patients allergic to test compounds #3 patients with megaloblastic anemia due to folate deficiency #4 No consent is given from the patient him/herself nor a legally authorized representative/guardian of the patient #5 patients principal investigator judged inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate 6 weeks after treatment initiation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) reduction ratio of affected brain area 4 weeks after treatment initiation 2) duration of medication 3) incidence of abdominal symptoms 4) incidence of pancytopenia 5) incidence of acute renal failure 6) incidence of hepatic dysfunction 7) incidence of skin eruption (e.g. erythema) | — |
Contacts
Public ContactKei Yamamoto
Japan Institute for Health Security National Center for Global Health and Medicine
Outcome results
None listed